3. PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation

4. Genetics PCSK9

5. PCSK9-Directed Therapies in Development

6. Alirocumab (SAR236553) Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin

7. Evolocumab (AMG 145) Change in LDL-C at 2- and 4-Week Dosing Intervals on Statin Therapy

8. MENDEL Evolocumab Monotherapy for Hypercholesterolemia

9. LAPLACE-TIMI 57 Evolocumab Combined With Statin for Hypercholesterolemia

10. Statins Approximate LDL-C Lowering Efficacy

11. ENHANCE Simvastatin/Ezetimibe in FH

12. Effect of Alirocumab on LDL-C in Heterozygous FH

13. RUTHERFORD Effect of Evolocumab on LDL-C in Heterozygous FH

14. GAUSS Evolocumab in Statin Intolerance

15. PCSK9-Directed Therapies in Development

16. OSLER Extension Study

17. OSLER Effect of Evolocumab on LDL-C after 52 Weeks

18. Clinical Utility of PCSK9 Inhibitors

19. Phase 3 Trials

20. Use of PCSK9 Inhibitors Based on Evidence or Definitive Outcomes Data?

21. Abbreviations

22. Abbreviations (cont)

23. References

24. References (cont)

25. References (cont)